European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who…
